Lung Cancer | Specialty

The lung cancer condition center is a comprehensive resource for clinical news and expert insights on lung cancer. Read more at OncLive.

FDA Grants Orphan Drug Designation to CID-078 for SCLC

June 16th 2025

The FDA has granted orphan drug designation to CID-078 for the treatment of patients with small cell lung cancer.

Five Under 5: Top Oncology Videos for the Week of 6/8

June 15th 2025

The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.

The OncFive: Top Oncology Updates for the Week of 6/8

June 14th 2025

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.

TT125-802 Demonstrates Potential in Advanced NSCLC and Solid Tumors

June 13th 2025

TT125-802 demonstrated early clinical activity and a favorable safety profile in advanced solid tumors.

Looking Ahead: Potential Sequencing Strategies and Focusing On a Patient-Centered Approach to Treatment of HER2-Mutated NSCLC

June 13th 2025

Panelists discuss how sequencing strategies for multiple HER2-targeted therapies will require careful consideration of patient characteristics, disease burden, and prior treatments, with oral tyrosine kinase inhibitors potentially preferred first due to better tolerability and CNS activity, while combination approaches remain investigational pending safety and efficacy data.

Emerging Oral HER2-Targeted TKIs (Zongertinib and Sevabertinib): Efficacy and Safety in HER2-Mutated NSCLC

June 13th 2025

Panelists discuss how emerging oral tyrosine kinase inhibitors like zongertinib (HER2-selective) and sevabertinib (HER2/EGFR dual inhibitor) offer promising alternatives to antibody-drug conjugates with improved tolerability profiles, better central nervous system penetration, and robust response rates in the 60% to 70% range for second-line treatment.

Recognizing and Treating Interstitial Lung Disease Associated With Trastuzumab Deruxtecan

June 13th 2025

Panelists discuss how interstitial lung disease represents a critical and potentially cryptic toxicity occurring in 10% to 15% of patients receiving HER2 antibody-drug conjugates, requiring vigilant monitoring, prompt recognition of subtle symptoms like dry cough, and aggressive management with steroids and pulmonary consultation.

Antibody-Drug Conjugate Efficacy and Safety in HER2-Mutated NSCLC

June 13th 2025

Panelists discuss how antibody drug conjugates like trastuzumab deruxtecan work as “Trojan horses” to deliver chemotherapy directly to tumor cells, providing effective second-line treatment for patients with HER2-mutated disease but requiring careful management of chemotherapy-like adverse effects, including significant toxicities.

Clinical Implications and Frontline Treatment of HER2-Mutated NSCLC

June 13th 2025

Panelists discuss how patients with HER2-mutated lung cancer represent a high-risk population with aggressive biology and propensity for brain metastases, currently treated with standard chemotherapy in the frontline setting while awaiting clinical trials that may move HER2-targeted agents to first-line treatment.

HER2 Alteration Testing In Advanced and Metastatic NSCLC

June 13th 2025

Panelists discuss how comprehensive next-generation sequencing testing is essential for identifying HER2 mutations in patients with stage IV non–small cell lung cancer, distinguishing between HER2 mutations (detected by DNA sequencing) and HER2 overexpression/amplification (detected by immunohistochemistry).

Dr Jankowski on the Telomere-Targeted Agent THIO With Cemiplimab in Advanced NSCLC

June 12th 2025

Tomasz Jankowski, MD, PhD, discusses THIO sequenced with cemiplimab for the third-line treatment of patients with ICI-resistant advanced NSCLC.

MVdeltaC Receives FDA Orphan Drug Designation in Pleural Mesothelioma

June 12th 2025

The oncolytic virus candidate MVdeltaC has received FDA orphan drug designation for the treatment of patients with pleural mesothelioma.

Looking Ahead: Treatment Advancements and Multidisciplinary Perspectives on the Future of Early-Stage NSCLC Care

June 12th 2025

Panelists discuss how medical professionals envision the future of early-stage non–small cell lung cancer (NSCLC) treatment evolving through the integration of novel therapies, predictive biomarkers, and personalized strategies to address current gaps in care, emphasizing the need for continued research to optimize outcomes and tailor interventions in resectable disease.

Dr Gutierrez on Dato-DXd Plus Rilvegostomig in Advanced/Metastatic NSCLC

June 11th 2025

Martin E. Gutierrez, MD, discusses data for Dato-DXd plus rilvegostomig in advanced or metastatic NSCLC.

Dr Gonzalez Velez on the Role of Tarlatamab As Second-Line Treatment For SCLC

June 11th 2025

Miguel Gonzalez Velez, MD, discusses the role of tarlatamab as a second-line treatment for small cell lung cancer.

Dr Pennell on the Significance of the FDA Approval of Taletrectinib for ROS1+ NSCLC

June 11th 2025

Nathan A. Pennell, MD, PhD, discusses the significance of the FDA approval of taletrectinib for ROS1-positive non-small cell lung cancer.

Dr Zhang on Sacituzumab Tirumotecan in Pretreated Advanced EGFR-Mutated NSCLC

June 11th 2025

Li Zhang, MD, discusses sacituzumab tirumotecan in patients with previously treated, advanced EGFR-mutated non–small cell lung cancer.

FDA Approves Taletrectinib for ROS1+ Advanced NSCLC

June 11th 2025

The FDA has approved taletrectinib for use in patients with ROS1-positive advanced non–small cell lung cancer.

Sacituzumab Tirumotecan Plus Tagitanlimab Receives Breakthrough Therapy Designation in China for First-Line, Nonsquamous NSCLC

June 11th 2025

China’s Center for Drug Evaluation granted breakthrough therapy designation to sacituzumab tirumotecan for nonsquamous non–small cell lung cancer.

First-Line Lurbinectedin Plus Atezolizumab Maintenance Under Priority Review for ES-SCLC

June 10th 2025

The FDA granted priority review to the sNDA seeking the approval of the first-line maintenance combination of lurbinectedin and atezolizumab for ES-SCLC.